Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use

Kim,Kyoung-Yoon; Yi,Bo-Rim; Lee,Hye-Rim; Kang,Nam-Hee; Jeung,Eui-Bae; Kim,Seung U.; Choi,Kyung-Chul

doi:10.3892/ijo.2011.1288

Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use

Authors:
- Kyoung-Yoon Kim
- Bo-Rim Yi
- Hye-Rim Lee
- Nam-Hee Kang
- Eui-Bae Jeung
- Seung U. Kim
- Kyung-Chul Choi
View Affiliations

Affiliations: Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea, Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 361-763, Republic of Korea
Published online on: December 8, 2011 https://doi.org/10.3892/ijo.2011.1288
Pages: 1097-1104

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Genetically engineered stem cells (GESTECs) producing suicide enzymes and immunotherapeutic cytokines have therapeutic effects on tumors, and may possibly reduce the side effects of toxic drugs used for treatments. Suicide enzymes can convert non-toxic pro-drugs to toxic metabolites that can reduce tumor growth. Cytosine deaminase (CD) is a suicide enzyme that metabolizes a non-toxic pro-drug, 5-fluorocytosine (5-FC), into the cytotoxic agent, 5-fluorouracil (5-FU). As an immunotherapeutic agent, human interferon‑β (IFN‑β) has anticancer effects. In this study, we used modified human neural stem cells (HB1.F3) expressing the Escherichia coli (E. coli) CD gene (HB1.F3.CD) or both the CD and human IFN‑β genes (HB1.F3.CD.IFN‑β) and evaluated their effectiveness on gastric carcinoma cells (AGS); migration of GESTECs to AGS was analyzed as well as formation of 5-FU and IFN‑β. Reverse transcription-polymerase chain reaction (RT-PCR) was used to confirm the expression of CD and IFN‑β genes in GESTECs along with confirming the production of chemoattractant molecules such as stem cell factor (SCF), CXCR4, c-Kit, vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2). In addition, by co-culturing GESTECs with AGS in the presence of 5-FC, we were able to confirm that cancer growth was inhibited, along with a synergistic effect when the CD and IFN‑β genes (HB1.F3.CD.IFN‑β) were co-expressed. Indeed a marked anticancer effect was demonstrated when the CD and IFN‑β genes were expressed together compared to expression of the CD gene alone (HB1.F3.CD). According to a modified transwell migration assay, the migration of GESTECs toward AGS was confirmed. In conclusion, these data suggest potential application of GESTECs to gastric cancer therapy, due to a remarkable synergistic effect of CD and IFN‑β genes in the presence of 5-FC. Additionally, the tumor-selective migration capability in vitro suggests that GESTECs are a potential anticancer therapy candidate that may result in minimal side effects compared to the conventional chemotherapy.

View Figures

View References

1	Isik M, Caner S, Metin Seker M, et al: Gastric adenocarcinoma under the age of 40; more metastatic, less differentiated. J BUON. 16:253–256. 2011.PubMed/NCBI
2	Blum M, Suzuki A and Ajani JA: A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol. 7:715–726. 2011. View Article : Google Scholar : PubMed/NCBI
3	Fidan E, Fidan S, Yildiz B, et al: Bolus fluorouracil induced syncope and pulseless ventricular tachycardia: a case report. Hippokratia. 15:93–95. 2011.PubMed/NCBI
4	Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
5	Luo XR, Li JS, Niu Y and Miao L: Targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell. Mol Biol Rep. 38:1201–1207. 2011. View Article : Google Scholar : PubMed/NCBI
6	Anderson LM, Krotz S, Weitzman SA and Thimmapaya B: Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther. 7:845–852. 2000.PubMed/NCBI
7	Joo KM, Park IH, Shin JY, et al: Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther. 17:570–575. 2009. View Article : Google Scholar : PubMed/NCBI
8	Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res. 62:3603–3608. 2002.
9	Zhang JF, Wei F, Wang HP, et al: Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J Exp Clin Cancer Res. 29:522010. View Article : Google Scholar : PubMed/NCBI
10	Aboody KS, Brown A, Rainov NG, et al: Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA. 97:12846–12851. 2000. View Article : Google Scholar : PubMed/NCBI
11	Aboody KS, Bush RA, Garcia E, et al: Development of a tumor-selective approach to treat metastatic cancer. PLoS One. 1:e232006. View Article : Google Scholar : PubMed/NCBI
12	Kim SK, Kim SU, Park IH, et al: Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res. 12:5550–5556. 2006. View Article : Google Scholar
13	Kim KY, Kim SU, Leung PC, Jeung EB and Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci. 101:955–962. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kim SU: Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology. 24:159–171. 2004. View Article : Google Scholar : PubMed/NCBI
15	Kim SU, Nakagawa E, Hatori K, Nagai A, Lee MA and Bang JH: Production of immortalized human neural crest stem cells. Methods Mol Biol. 198:55–65. 2002.PubMed/NCBI
16	Evoy D, Hirschowitz EA, Naama HA, et al: In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res. 69:226–231. 1997. View Article : Google Scholar : PubMed/NCBI
17	Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ and Crystal RG: In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther. 6:1055–1063. 1995.PubMed/NCBI
18	Kanai F, Lan KH, Shiratori Y, et al: In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 57:461–465. 1997.
19	Lan KH, Kanai F, Shiratori Y, et al: Tumor-specific gene expression in carcinoembryonic antigen - producing gastric cancer cells using adenovirus vectors. Gastroenterology. 111:1241–1251. 1996. View Article : Google Scholar : PubMed/NCBI
20	Li Z, Shanmugam N, Katayose D, et al: Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther. 4:113–117. 1997.PubMed/NCBI
21	Austin EA and Huber BE: A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol. 43:380–387. 1993.PubMed/NCBI
22	Mullen CA, Kilstrup M and Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA. 89:33–37. 1992. View Article : Google Scholar : PubMed/NCBI
23	Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol. 13:1663–1670. 1995.PubMed/NCBI
24	Pinedo HM and Peters GF: Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 6:1653–1664. 1988.PubMed/NCBI
25	Chung-Faye GA, Chen MJ, Green NK, et al: In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 8:1547–1554. 2001. View Article : Google Scholar
26	Crystal RG, Hirschowitz E, Lieberman M, et al: Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther. 8:985–1001. 1997.PubMed/NCBI
27	Freytag SO, Khil M, Stricker H, et al: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62:4968–4976. 2002.
28	Dong Z, Greene G, Pettaway C, et al: Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-β. Cancer Res. 59:872–879. 1999.PubMed/NCBI
29	Rossiello F, De Cicco Nardone F and Dell’Acqua S: Interferon-β increases the sensitivity of endometrial cancer cells to cell-mediated cytotoxicity. Gynecol Oncol. 54:130–136. 1994.
30	Yi BR, Hwang KA, Kang NH, Kim SU, Jeung EB and Choi KC: Antitumor therapeutic effects of cytosine deaminase and interferon-β against endometrial cancer cells using genetically engineered stem cells in vitro. Anticancer Res. 31:2853–2862. 2011.
31	Yi BR, O SN, Kang NH, et al: Genetically engineered stem cells expressing cytosine deaminase and interferon-β migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects. Int J Oncol. 39:833–839. 2011.
32	Schmidt NO, Przylecki W, Yang W, et al: Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia. 7:623–629. 2005. View Article : Google Scholar : PubMed/NCBI
33	Sun L, Lee J and Fine HA: Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest. 113:1364–1374. 2004. View Article : Google Scholar : PubMed/NCBI
34	Ehtesham M, Yuan X, Kabos P, et al: Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia. 6:287–293. 2004. View Article : Google Scholar : PubMed/NCBI
35	Jeong SW, Chu K, Jung KH, Kim SU, Kim M and Roh JK: Human neural stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage. Stroke. 34:2258–2263. 2003. View Article : Google Scholar : PubMed/NCBI
36	Kim SU, Park IH, Kim TH, et al: Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease. Neuropathology. 26:129–140. 2006. View Article : Google Scholar
37	Meng XL, Shen JS, Ohashi T, Maeda H, Kim SU and Eto Y: Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. J Neurosci Res. 74:266–277. 2003. View Article : Google Scholar : PubMed/NCBI
38	Rosser AE, Zietlow R and Dunnett SB: Stem cell transplantation for neurodegenerative diseases. Curr Opin Neurol. 20:688–692. 2007. View Article : Google Scholar : PubMed/NCBI
39	Ryu JK, Kim J, Cho SJ, et al: Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol Dis. 16:68–77. 2004. View Article : Google Scholar : PubMed/NCBI
40	Lee ST, Chu K, Park JE, et al: Intravenous administration of human neural stem cells induces functional recovery in Huntington’s disease rat model. Neurosci Res. 52:243–249. 2005.PubMed/NCBI
41	Lee DH, Ahn Y, Kim SU, et al: Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res. 15:4925–4934. 2009. View Article : Google Scholar : PubMed/NCBI
42	Boucher PD, Im MM, Freytag SO and Shewach DS: A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res. 66:3230–3237. 2006. View Article : Google Scholar : PubMed/NCBI
43	Hartmann KU and Heidelberger C: Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. J Biol Chem. 236:3006–3013. 1961.PubMed/NCBI
44	Wei J, Wahl J, Knauss H, et al: Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells. Cancer Gene Ther. 14:640–651. 2007. View Article : Google Scholar : PubMed/NCBI
45	Huber BE, Austin EA, Richards CA, Davis ST and Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA. 91:8302–8306. 1994. View Article : Google Scholar
46	Saukkonen K and Hemminki A: Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther. 4:683–696. 2004. View Article : Google Scholar
47	Tubiana M: Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol. 28:113–121. 1989. View Article : Google Scholar : PubMed/NCBI
48	Beppu K, Jaboine J, Merchant MS, Mackall CL and Thiele CJ: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst. 96:46–55. 2004. View Article : Google Scholar : PubMed/NCBI
49	Sun L, Hui AM, Su Q, et al: Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 9:287–300. 2006. View Article : Google Scholar : PubMed/NCBI
50	Nakamizo A, Marini F, Amano T, et al: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65:3307–3318. 2005.PubMed/NCBI